Immunogenicity and Efficacy of Anti-Hepatitis B Vaccines in Hemodialysis Patients

Abstract
The 7-year follow-up with plasma-derived and 2-year follow-up with r-DNA vaccines have indicated the safety, immunogenicity and persistence of a vaccine-induced antibody response in hemodialysis patients. The results of our study indicate that these subjects have a lower and often inadequate immunogenic response to the HB vaccine and that the r-DNA vaccine gives a better seroconversion rate than the plasma-derived vaccines.

This publication has 0 references indexed in Scilit: